Gilead is heading to the all time high
Gilead Sciences is one of the largest antiviral producers in the world. Covid 19 pandemic showed that the greatest threat to the existence of humanity comes from Viral infections not wars or other natural disasters.
Gilead has hundreds of untested patented antiviral agents that can helps in these kind of situations. Finding the cure for the hardest diseases like HIV, HCV and now Covid 19, is a good proof how strategic this company is.
Gilead fundamentally is strong too. More than 20B cash in the accounts speeds up the growth. They have bought 3 small cancer research companies in 3 months. In my opinion, Gilead has started a bulish longterm trend and with the help of Remdesivir sales it can reach the all time high.
I m long GILD and I will add to the position if it breaks the resistance at 78.
Gilead has hundreds of untested patented antiviral agents that can helps in these kind of situations. Finding the cure for the hardest diseases like HIV, HCV and now Covid 19, is a good proof how strategic this company is.
Gilead fundamentally is strong too. More than 20B cash in the accounts speeds up the growth. They have bought 3 small cancer research companies in 3 months. In my opinion, Gilead has started a bulish longterm trend and with the help of Remdesivir sales it can reach the all time high.
I m long GILD and I will add to the position if it breaks the resistance at 78.
코멘트:
Gilead missed the expected Rev for 500 million. They spent more than 5B in research and acquisitions. The rev from Remdesivir has not shown up in the statements.
I think fundamentally the company is solid. 21B in cash and many great breakthrough medications in the pipeline for cancers and HIV.
The target is intact and it goes to all time high after hitting the retail stoploss
I think fundamentally the company is solid. 21B in cash and many great breakthrough medications in the pipeline for cancers and HIV.
The target is intact and it goes to all time high after hitting the retail stoploss
Gilead Sciences (GILD) said Friday its experimental coronavirus treatment, remdesivir, lowered the risk of death by 62% in a Phase 3 study — prodding GILD stock higher.
The biotech company analyzed a Phase 3 study and real-world patients with severe Covid-19. It found remdesivir not only improved clinical recovery, but reduced the risk of death by 62% overall compared with those who received standard drugs. Still, Gilead noted the finding hasn't been confirmed in a clinical study.